Physician profile
Ali Melhem
NPI 1285788430
$681,193.47
in general payments reported to CMS, 2019-2025
16 companies · $123K in 2025
The $123K reported for 2025 was more than what 99% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $145K · 2020: $62K · 2021: $58K · 2022: $51K · 2023: $140K · 2024: $103K · 2025: $123K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $287K · Travel and Lodging: $63K · Consulting Fee: $8,998 · Food and Beverage: $7,196 · Education: $111.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $286,639.50 |
| Travel and Lodging | $63,330.17 |
| Consulting Fee | $8,998.00 |
| Food and Beverage | $7,195.88 |
| Education | $111.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $401,233.83 | 2021-2025 | |
| Allergan, INC. | $107,658.39 | 2019-2021 | |
| Neurocrine Biosciences, INC. | $105,937.37 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $30,966.37 | 2024-2025 | Cobenfy |
| Otsuka America Pharmaceutical, INC. | $24,408.32 | 2019-2022 | |
| Alkermes, INC. | $9,199.49 | 2022-2025 | Lybalvi, Aristada, Aristada Initio |
| Novocure INC. | $877.57 | 2020-2024 | Optune |
| Axsome Therapeutics, INC. | $294.22 | 2023-2025 | Auvelity |
| Teva Pharmaceuticals USA, INC. | $127.18 | 2019-2024 | |
| Acadia Pharmaceuticals INC | $116.27 | 2024 | Nuplazid |
| Vanda Pharmaceuticals INC. | $87.67 | 2024-2025 | Hetlioz, Fanapt |
| Abbott Laboratories | $82.65 | 2023 | Proclaim |
| Janssen Pharmaceuticals, INC | $77.88 | 2019-2020 | |
| Cognoa, INC. | $68.70 | 2023 | Canvas Dx |
| Lundbeck LLC | $43.19 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $14.37 | 2023 | Watchman Access System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ali Melhem listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.